** Shares of drugmaker Abeona Therapeutics ABEO.O up 12.7% at $6.03 premarket
** ABEO says the U.S. FDA has approved its gene therapy for a rare skin disorder
** The gene therapy, called Zevaskyn, is approved to treat adult and pediatric patients with recessive dystrophic epidermolysis bullosa
** The current standard-of-care treatment is daily wound care and protective bandaging
** Company says the treatment is expected to be available in Q3 2025
** As of last close, ABEO shares down 4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。